Antibodies are cloned and used to attack one specific type of protein found in cancer cells.
Daratumumab is a drug used for the treatment of multiple myeloma. It is for use in people who have multiple myeloma who have already received at least one prior therapy. It is given as an injection into a vein through an IV.
Ipilimumab is a cancer medication that interferes with the growth and spread of cancer cells in the body. It is approved to treat melanoma. It is also being studied in the treatment of other types of cancers, including multiple myeloma.
Normally, your immune system helps defend against internal threats, such as cancer, using specialized immune cells called T cells. Some types of cancer cells present a protein called PD-L1, which interacts with the PD-1 receptor on your T cells. This can deactivate your T cells and prevent them from recognizing and attacking the cancer. Nivolumab blocks the PD-1 receptor on T cells and can halt the effects on PD-L1 on T cells, allowing them to be active and do their job.
GSK2857916 is an antibody-drug conjugate (ADC) with anti-BCMA antibody that binds to BCMA on tumor cell surfaces causing cell cycle arrest and inducing antibody-dependent cellular cytotoxicity (ADCC).
SEA-BCMA is a new antibody targeting the BCMA protein and being tested in multiple myeloma.
Atezolizumab is a new drug being tested in myeloma. It targets a protein called PDL-1 which is normally involved in dampening the immune response. This increases the activity of the immune system to recognize and destroy myeloma cells.
Cetuximab is a cancer medication that interferes with the growth and spread of cancer cells in the body. It is approved to treat colorectal cancer and squamous cell carcinoma of the head and neck. It is also being studied in the treatment of other types of cancers, including multiple myeloma.
SGN-CD48A is a novel humanized anti-cd48 antibody-drug conjugate being tested for the treatment of multiple myeloma.
BION-1301 is a humanized antibody that blocks A PRoliferation-Inducing Ligand (APRIL) from binding to its receptors, using Aduro’s B-select monoclonal antibody platform. In preclinical studies, BION-1301 eliminated malignant cells and reduced resistance to therapy in models of multiple myeloma.
Elotuzumab is a drug used for the treatment of multiple myeloma. It is for use in patients who have received one to three prior medications and is intended to be used in combination with lenalidomide and dexamethasone. It is given as an injection into a vein through an IV.
Denosumab is a humanized monoclonal antibody that binds to RANKL and blocks the interaction of RANKL with RANK, resulting in inhibition of bone destroying cells and a decrease in bone breakdown.
TAK-079 is a fully human, non-agonistic, IgG1 cell-depleting monoclonal antibody that binds human CD38 with high affinity.
SAR650984 is a humanized IgG1 monoclonal antibody that binds to CD38+ cells, triggerring antitumoral antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and tumor programmed cell death.
One way your immune system controls the activity of T cells is through the PD-1 pathway. Some cancer cells can hide from the T cells attack by taking control of the PD-1 pathway. This stops T cells from attacking cancer cells. Pembrolizumab works by blocking the PD-1 pathway. The Keynote Clinical Trials are studying whether pembrolizumab can help treat patients with various types of cancer.One way your immune system controls the activity of T cells is through the PD-1 pathway. Some cancer cells can hide from the T cells attack by taking control of the PD-1 pathway. This stops T cells from attacking cancer cells. Pembrolizumab works by blocking the PD-1 pathway. The Keynote Clinical Trials are studying whether pembrolizumab can help treat patients with various types of cancer.
An antibody-drug conjugate (ADC) composed of a proprietary monoclonal antibody against an unnamed tumor-associated antigen (TAA) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of MEDI7247 targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the TAA-expressing cancer cells, through an as of yet unknown mechanism of action.
Lintuzumab AC 225 is an Antibody Radio-Conjugate (ARC) comprised of the anti-CD33 monoclonal antibody lintuzumab labeled with the radioisotope actinium-225.
AMG-224 is a new drug being tested in myeloma called an antibody-drug conjugate comprised of anti-BCMA–MCC–DM1. It consists of a chemotherapy drug combined with a monoclonal antibody which helps to deliver the drug to myeloma cells.
Cemiplimab REGN2810 is a fully human anti-PD-1 monoclonal antibody.
Durvalumab is an investigational human monoclonal antibody directed against programmed death ligand-1 (PD-L1). PD-L1 can be expressed by tumours to evade detection by the immune system through binding to PD-1 on cytotoxic T lymphocytes. Durvalumab blocks the PD-L1 interaction with PD-1, countering the tumour's immune-evading tactics. Durvalumab is being developed, alongside other immunotherapies, to strengthen the patient's immune system and attack the cancer.
SGN-CD352A is an antibody drug conjugate that can work by targeting specific areas of the cancer cell, attacking it, and inducing rapid cell death.
SRF231 is a fully human monoclonal antibody that targets and inhibits the activity of the CD47 protein that is highly expressed in cancer cells. CD47 works as a signal that prevents cancer cells from being recognized by the immune system and macrophages. By blocking CD47 signaling, SRF231 may allow macrophages to recognize and destroy cancer cells.
Create your account today and get matched to myeloma treatments and trials around the US.
Weekdays 9am - 5pm EST